Vnitr Lek 2008, 54(5):508-510

System rennin-aldosterone in fat tissue and other organ and tissues

Š. Svačina
III. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA

Important mechanism of pathogenesis of hypertension in obesity is renin-aldosterone system in adipose tissue. Adrenal cells can be also stimulated to aldosterone secretion by local adrenal fat cells and also by other factors from fat tissue (lipids, endocrine disruptors). Local system renin-aldosteron is active also in other tissues and organs in obesity related hypertension. Feed back is closed by recently investigated fact that aldosteron hypersecretion can cause metabolic syndrome. Between systemic approach to obesity a new phenomenon of organ obesity is coming - adipokines from local fat cells can influence organ and tissue function e.g. in essential hypertension.

Keywords: hypertension; obesity; metabolic syndrom; mineralocorticoids; endocrine disruptors

Received: February 24, 2008; Published: May 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Svačina Š. System rennin-aldosterone in fat tissue and other organ and tissues. Vnitr Lek. 2008;54(5):508-510.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Carey RM (ed). Hypertension and hormon mechanism. Totowa: Humana Press 2007.
    2. Della Mea P, Lupia M, Bandolin V et al. Adiponectin, insulin resistance, and left ventricular structure in dipper and non-dipper essential hypertensive patients. Am J Hypertens 2005; 18: 30-35. Go to original source... Go to PubMed...
    3. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci USA 2003; 100: 14211-14216. Go to original source... Go to PubMed...
    4. Fallo F, Veglio F, Bertello C et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 2006; 91: 454-459. Go to original source... Go to PubMed...
    5. Fantuzzi C, Mazzone T. Adipose Tissue and Adipokines in Health and Disease. Totowa: Humana Press 2007. Go to original source...
    6. Garrison RJ, Kannel WB, Stokes J 3rd, Castelli WP. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 1987; 16: 235-251. Go to original source... Go to PubMed...
    7. Goodfriend TL, Egan BM, Kelley DE. Aldosterone in obesity. Endocr Res 1998; 24: 789-796. Go to original source... Go to PubMed...
    8. Hinson JP, Raven PW. Effects of endocrine-disrupting chemicals on adrenal function. Best Pract Res Clin Endocrinol Metab 2006; 20: 111-120. Go to original source... Go to PubMed...
    9. Lamounier-Zepter V, Rotthoff T, Ansurudeen I et al. Increased aldosterone/renin quotient in obese hypertensive women: a novel role for low-density lipoproteins? Horm Metab Res 2006; 38: 471-475. Go to original source... Go to PubMed...
    10. Lamounier-Zepter V, Ehrhart-Bornstein M. Fat tissue metabolism and adrenal steroid secretion. Curr Hypertens Rep 2006; 8: 30-34. Go to original source... Go to PubMed...
    11. Lamounier-Zepter V, Ehrhart-Bornstein M, Bornstein SR. Mineralocorticoid-stimulating activity of adipose tissue. Best Pract Res Clin Endocrinol Metab 2005; 19: 567-575. Go to original source... Go to PubMed...
    12. Lazartigues E, Feng Y, Lavoie JL. The two fACEs of the tissue renin-angiotensin systems: implication in cardiovascular diseases. Curr Pharm Des 2007; 13: 1231-1245. Go to original source... Go to PubMed...
    13. Sharma AM, Grassi G. Obesity and hypertension: cause or consequence? J Hypertens 2001; 19: 2125-2126. Go to original source... Go to PubMed...
    14. Svačina Š. Hypertenze při obezitě a diabetu. Praha: Triton 2007.
    15. Svačina Š. Víme, proč vzniká hypertenze u obezity? In: Widimský J (ed). Arteriální hypertenze - současné trendy. V. symposium. Praha: Triton 2007: 35-41.
    16. Svačina Š. Hyperaldosteronizmus, obezita a metabolický syndrom. In: Widimský J (ed). Arteriální hypertenze - současné trendy. V. symposium. Praha: Triton 2007.
    17. Thakur V, Richards R, Reisin E. Obesity, hypertension, and the heart. Am J Med Sci 2001; 321: 242-248. Go to original source... Go to PubMed...
    18. Vela D, Buja LM, Madjid M et al. The role of periadventitial fat in atherosclerosis. Arch Pathol Lab Med 2007; 131: 481-487. Go to original source...
    19. Verlohren S, Dubrovska G, Tsang SY et al. Visceral periadventitial adipose tissue regulates arterial tone of mesenteric arteries. Hypertension 2004; 44: 271-276. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.